IQVIA (NYSE:IQV) Hits New 52-Week Low – Should You Sell?

IQVIA Holdings Inc. (NYSE:IQV) shares reached a new 52-week low on Tuesday . The company traded as low as $169.37 and last traded at $176.28, with a volume of 2234715 shares changing hands. The stock had previously closed at $177.39.

Wall Street Analyst Weigh In

IQV has been the topic of several recent analyst reports. Stifel Nicolaus lowered their target price on shares of IQVIA from $273.00 to $261.00 and set a “buy” rating on the stock in a research note on Friday, February 7th. StockNews.com downgraded IQVIA from a “buy” rating to a “hold” rating in a research report on Wednesday, March 12th. Truist Financial restated a “buy” rating and issued a $263.00 price objective (up from $261.00) on shares of IQVIA in a research report on Monday, February 10th. UBS Group decreased their target price on IQVIA from $260.00 to $255.00 and set a “buy” rating on the stock in a research report on Friday, February 7th. Finally, Barclays reduced their price objective on shares of IQVIA from $255.00 to $235.00 and set an “overweight” rating for the company in a research report on Monday, February 3rd. Five analysts have rated the stock with a hold rating, sixteen have given a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $249.05.

IQVIA Stock Up 1.9 %

The business has a fifty day moving average of $191.43 and a 200 day moving average of $204.92. The company has a debt-to-equity ratio of 2.12, a current ratio of 0.84 and a quick ratio of 0.84. The stock has a market capitalization of $30.77 billion, a price-to-earnings ratio of 23.27, a PEG ratio of 1.99 and a beta of 1.50.

IQVIA (NYSE:IQV) last released its quarterly earnings results on Thursday, February 6th. The medical research company reported $2.90 earnings per share for the quarter, missing analysts’ consensus estimates of $3.11 by ($0.21). IQVIA had a return on equity of 28.81% and a net margin of 8.91%. As a group, equities analysts predict that IQVIA Holdings Inc. will post 10.84 earnings per share for the current year.

Institutional Investors Weigh In On IQVIA

A number of institutional investors and hedge funds have recently made changes to their positions in the stock. Norges Bank acquired a new stake in IQVIA in the 4th quarter valued at approximately $336,041,000. Raymond James Financial Inc. purchased a new stake in shares of IQVIA in the 4th quarter valued at $236,120,000. American Century Companies Inc. lifted its stake in IQVIA by 396.0% during the 4th quarter. American Century Companies Inc. now owns 1,134,737 shares of the medical research company’s stock worth $222,987,000 after acquiring an additional 905,960 shares in the last quarter. Invesco Ltd. boosted its holdings in IQVIA by 53.4% during the 4th quarter. Invesco Ltd. now owns 2,590,260 shares of the medical research company’s stock valued at $509,012,000 after acquiring an additional 902,226 shares during the period. Finally, Canada Pension Plan Investment Board increased its stake in IQVIA by 20.0% during the fourth quarter. Canada Pension Plan Investment Board now owns 4,282,024 shares of the medical research company’s stock worth $841,461,000 after purchasing an additional 712,958 shares during the period. 89.62% of the stock is owned by hedge funds and other institutional investors.

About IQVIA

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.